Osteoporosis Market Forecast

Introduction

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Reasons to Purchase

• Understand current and future osteoporosis drug market dynamics
• Gain insight into the unmet needs of current osteoporosis treatment and to what extent pipeline drugs will address these issues
• Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK